Altamira Therapeutics (formerly Auris Medical) said that the European Patent Office (EPO) has issued a notice that it will grant a patent (No. 3698791) covering the company’s AM-125 intranasal formulation of betahistine until February 2038. Altamira says that it has been granted composition of matter and methods of use patents for intranasal betahistine in 50 countries.
In 2020, Auris Medical reported that a Phase 2 study of AM-125 for the treatment of vertigo improved demonstrated statistically significant improvement in balance for all doses tested. Altamira’s web site currently lists both AM-125 and Bentrio bentonite-based nasal spray for protection against allergens as “legacy programs” that it is looking to out-license or divest.
Altamira Therapeutics CEO Thomas Meyer commented, “We are very pleased with the continued expansion of our patent portfolio covering the intranasal betahistine program. Securing our intellectual property is pivotal as we strategically position our company around our RNA delivery platform. With considerable interest from various parties, we anticipate collaborating with the appropriate partners to bring the AM-125 program to patients worldwide who are suffering from dizziness.”
Read the Altamira Therapeutics press release.
